Research In Brief
This article was originally published in The Gray Sheet
Executive Summary
Heart attacks in women: Women with non-ST-segment elevation acute coronary syndrome (NSTE ACS) benefit as much as men from coronary intervention, according to a meta-analysis of eight randomized clinical trials including 3,075 women and 7,075 men. Results of the study, led by Michelle O'Donoghue, Brigham and Women's Hospital in Boston, appear in the July 2 Journal of the American Medical Association. The eight trials, conducted between 1970 and 2008, compared invasive treatment to conservative therapy of NSTE ACS and collected sex-specific data on death, myocardial infarction and rehospitalization for at least 12 months of follow-up. Among women with biomarkers showing they are at high risk for myocardial infarction, an invasive therapy reduced the risk of death, myocardial infarction or acute coronary syndrome by 33%. The invasive strategy was not associated with better outcomes in women without the biomarker for high risk
You may also be interested in...
Earnings Calls In Brief
Kinetic Concepts to retain therapeutic support systems biz: Kinetic Concepts says it will retain its formerly struggling Therapeutic Support Systems (TSS) business, which rebounded with 7% sales growth to $82.7 million in the fourth quarter of 2009, the firm reported Jan. 26. The firm initiated a review of the TSS business last fall after a third-quarter TSS sales drop of 10% (1"The Gray Sheet" Nov. 16, 2009). The fourth-quarter TSS results "suggest that the hospital environment is stabilizing after a tumultuous year," said CEO Catherine Burzik. The unit includes items such as hospital beds for wound care, bariatric and critical care patients. "After careful review, we have concluded that retaining this important business serves the best interest of our stakeholders," Burzik said. Corporate fourth-quarter revenue of $526.8 million was up 7% from last year (or 4% at constant currency). Kinetic Concepts notes that its long-standing U.S. negative pressure wound therapy (NPWT) patent case against competitor Smith & Nephew is on track for a February trial. A Japan launch of its V.A.C. Therapy technology for NPWT remains on deck for the second quarter of 2010. And the company plans to expand its European sales force from 26 to 35 reps by the end of March
Earnings Calls In Brief
Kinetic Concepts to retain therapeutic support systems biz: Kinetic Concepts says it will retain its formerly struggling Therapeutic Support Systems (TSS) business, which rebounded with 7% sales growth to $82.7 million in the fourth quarter of 2009, the firm reported Jan. 26. The firm initiated a review of the TSS business last fall after a third-quarter TSS sales drop of 10% (1"The Gray Sheet" Nov. 16, 2009). The fourth-quarter TSS results "suggest that the hospital environment is stabilizing after a tumultuous year," said CEO Catherine Burzik. The unit includes items such as hospital beds for wound care, bariatric and critical care patients. "After careful review, we have concluded that retaining this important business serves the best interest of our stakeholders," Burzik said. Corporate fourth-quarter revenue of $526.8 million was up 7% from last year (or 4% at constant currency). Kinetic Concepts notes that its long-standing U.S. negative pressure wound therapy (NPWT) patent case against competitor Smith & Nephew is on track for a February trial. A Japan launch of its V.A.C. Therapy technology for NPWT remains on deck for the second quarter of 2010. And the company plans to expand its European sales force from 26 to 35 reps by the end of March
New Label For Evicel Fibrin Sealant Could Boost Omrix/Ethicon Market Share
Omrix Biopharmaceuticals plans with the help of marketing partner Johnson & Johnson/Ethicon to take a larger share of the U.S. hemostasis market now that its Evicel fibrin sealant is approved for all types of surgery